CA2633266C - Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same - Google Patents

Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same Download PDF

Info

Publication number
CA2633266C
CA2633266C CA2633266A CA2633266A CA2633266C CA 2633266 C CA2633266 C CA 2633266C CA 2633266 A CA2633266 A CA 2633266A CA 2633266 A CA2633266 A CA 2633266A CA 2633266 C CA2633266 C CA 2633266C
Authority
CA
Canada
Prior art keywords
tablet
solid dispersion
pharmaceutically acceptable
fused solid
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2633266A
Other languages
English (en)
French (fr)
Other versions
CA2633266A1 (en
Inventor
Jong Soo Woo
Sang Wook Kim
Hong Gi Yi
Jae Kuk Ryu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of CA2633266A1 publication Critical patent/CA2633266A1/en
Application granted granted Critical
Publication of CA2633266C publication Critical patent/CA2633266C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2633266A 2005-12-16 2006-12-18 Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same Expired - Fee Related CA2633266C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2005-0124386 2005-12-16
KR20050124386 2005-12-16
PCT/KR2006/005526 WO2007069874A1 (en) 2005-12-16 2006-12-18 Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same

Publications (2)

Publication Number Publication Date
CA2633266A1 CA2633266A1 (en) 2007-06-21
CA2633266C true CA2633266C (en) 2011-08-02

Family

ID=38163142

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2633266A Expired - Fee Related CA2633266C (en) 2005-12-16 2006-12-18 Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same

Country Status (14)

Country Link
US (1) US20080292702A1 (enExample)
EP (1) EP1968542B1 (enExample)
JP (1) JP2009519326A (enExample)
CN (1) CN101330904B (enExample)
AU (1) AU2006325658B2 (enExample)
BR (1) BRPI0619868A8 (enExample)
CA (1) CA2633266C (enExample)
ES (1) ES2429097T3 (enExample)
IL (1) IL191804A0 (enExample)
NO (1) NO339674B1 (enExample)
NZ (1) NZ569813A (enExample)
RU (1) RU2403013C2 (enExample)
WO (1) WO2007069874A1 (enExample)
ZA (1) ZA200806138B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002731A (es) 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
KR101005391B1 (ko) * 2008-07-22 2010-12-30 한국콜마 주식회사 덱시부프로펜 함유 서방출성 시럽제 및 그의 제조방법
KR101067224B1 (ko) * 2008-07-22 2011-09-22 한국콜마 주식회사 이부프로펜 함유 서방출성 시럽제 및 그의 제조방법
CN101961306B (zh) * 2009-07-24 2011-11-09 北京化工大学 一种低熔点药物固体分散体的制备方法
CN102144982B (zh) * 2011-03-30 2012-12-12 江苏神龙药业有限公司 一种米诺膦酸片及其制备方法
CN102406940B (zh) * 2011-11-01 2013-07-03 温州大学 一种纳米级片状羧甲基淀粉钠在固体分散体中的应用
WO2013154511A1 (en) * 2012-04-13 2013-10-17 Mahmut Bilgic Film tablet formulations comprising dexibuprofen
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
JP6647902B2 (ja) * 2015-10-30 2020-02-14 株式会社ファンケル 徐放性顆粒剤
CN106265522A (zh) * 2016-08-30 2017-01-04 铜陵翔宇商贸有限公司 布洛芬‑pvp共沉淀物及其制备方法
JP7147262B2 (ja) * 2017-05-23 2022-10-05 大正製薬株式会社 固形製剤
JP7109255B2 (ja) * 2017-05-23 2022-07-29 ライオン株式会社 粉砕物の製造方法及び錠剤の製造方法
EP3658123A4 (en) * 2017-07-24 2021-04-28 Acryspharm LLC PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD
RU2685294C1 (ru) * 2018-05-10 2019-04-17 Общество с ограниченной ответственностью "ДИНОН" (ООО "ДИНОН") Поглотитель, способ его приготовления (варианты) и способ удаления диоксида углерода из газовых смесей
CN112263567B (zh) * 2020-10-19 2022-05-03 南京易亨制药有限公司 一种布洛芬缓释胶囊及制备方法
CN117363320B (zh) * 2023-12-07 2024-02-13 黑龙江省鑫博鑫交通科技有限公司 一种公路用融雪剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56120616A (en) * 1980-02-27 1981-09-22 Kaken Pharmaceut Co Ltd Ibuprofen-containing granule, its preparation, and internal medicine comprising it
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
CH669523A5 (enExample) * 1986-06-25 1989-03-31 Mepha Ag
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE69739165D1 (de) * 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
RU2246294C2 (ru) * 1999-12-09 2005-02-20 Дзе Бутс Компани ПЛС Терапевтические средства
GB0113839D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
AU2006325658A1 (en) 2007-06-21
EP1968542A4 (en) 2010-06-02
IL191804A0 (en) 2008-12-29
JP2009519326A (ja) 2009-05-14
HK1126671A1 (en) 2009-09-11
NO339674B1 (no) 2017-01-23
AU2006325658B2 (en) 2010-04-08
RU2403013C2 (ru) 2010-11-10
BRPI0619868A2 (pt) 2011-10-25
ZA200806138B (en) 2009-11-25
CA2633266A1 (en) 2007-06-21
BRPI0619868A8 (pt) 2016-06-07
ES2429097T3 (es) 2013-11-13
NZ569813A (en) 2011-07-29
CN101330904B (zh) 2012-04-18
RU2008129041A (ru) 2010-01-27
EP1968542A1 (en) 2008-09-17
EP1968542B1 (en) 2013-08-14
NO20083151L (no) 2008-09-05
WO2007069874A1 (en) 2007-06-21
US20080292702A1 (en) 2008-11-27
CN101330904A (zh) 2008-12-24

Similar Documents

Publication Publication Date Title
CA2633266C (en) Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
Tran et al. Controlled release systems containing solid dispersions: strategies and mechanisms
JP3045924B2 (ja) 放出が調整された経口薬剤調合物
JP5632367B2 (ja) Ｂｉｂｗ２９９２を含有する固形医薬製剤
JP4969104B2 (ja) 多孔質セルロース凝集体及びその成型体組成物
HU220075B (hu) Hosszan tartó hatóanyag-leadású morfintartalmú gyógyszerkészítmények és eljárás ezek előállítására
KR20070119700A (ko) 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제
JP2021105172A (ja) セルロース粉末、錠剤及び錠剤の製造方法
US12427113B2 (en) Cellulose composition, tablet, and orally disintegrating tablet
CN105732517A (zh) 包含烟酰胺为前驱体的5-氟尿嘧啶药物共晶的药物制剂及其制备方法
EP4056637B1 (en) Cellulose composition and tablet
JP2021075686A (ja) セルロース組成物、錠剤及び口腔内崩壊錠
KR20000069356A (ko) 급속방출식 약물전달 제형
TWI723621B (zh) 纖維素組合物、錠劑及口腔內崩散錠
MX2008007665A (en) Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
CA3158393C (en) Cellulose composition, tablet, and orally disintegrating tablet
HK1126671B (en) Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
CN120676932A (zh) 贝祖拉替尼制剂
Dewedar et al. FORMULATION AND EVALUATION OF CANDESARTAN CO-PRECIPITATE WITH HYDROPHILIC POLYMERS; PREPARATION OF ORODISPERSIBLE TABLETS
TW202118516A (zh) 纖維素組合物及錠劑

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181218